[1]单秋妹.德谷门冬双胰岛素与甘精胰岛素治疗口服降糖药控制不佳2型糖尿病的临床疗效[J].医学信息,2023,36(11):117-120.[doi:10.3969/j.issn.1006-1959.2023.11.023]
　SHAN Qiu-mei.Clinical Efficacy of Insulin Degludec and Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus with Poor Control of Oral Hypoglycemic Drugs[J].Journal of Medical Information,2023,36(11):117-120.[doi:10.3969/j.issn.1006-1959.2023.11.023]
点击复制

德谷门冬双胰岛素与甘精胰岛素治疗口服降糖药控制不佳2型糖尿病的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年11期
页码:
117-120
栏目:
论著
出版日期:
2023-06-01

文章信息/Info

Title:
Clinical Efficacy of Insulin Degludec and Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus with Poor Control of Oral Hypoglycemic Drugs
文章编号:
1006-1959（2023）11-0117-04
作者:
单秋妹
（天津市武清区人民医院内分泌科，天津 301700）
Author(s):
SHAN Qiu-mei
(Department of Endocrinology,Wuqing District People’s Hospital,Tianjin 301700,China)
关键词:
2型糖尿病; 口服降糖药控制不佳; 德谷门冬双胰岛素; 甘精胰岛素; 低血糖
Keywords:
Type 2 diabetes mellitus; Poor control of oral hypoglycemic drugs; insulin degludec/insulin aspart; Insulin glargine; Hypoglycemia
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2023.11.023
文献标志码:
A
摘要:
目的 探究德谷门冬双胰岛素（IDegAsp）与甘精胰岛素（IGlar）治疗口服降糖药控制不佳2型糖尿病（T2DM）的临床疗效。方法 以2020年3月-2022年3月天津市武清区人民医院收治的84例口服降糖药控制不佳T2DM患者为研究对象，采用随机数字表法分为IDegAsp组（42例）和IGlar组（42例），IDegAsp组应用德谷门冬双胰岛素治疗，IGlar组给予甘精胰岛素治疗，比较两组血糖指标[糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2 hPBG）]、血糖波动情况[最大血糖波动幅度（LAGE）、餐后血糖波动幅度（PPGE）]、胰岛功能[空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）]、体重指数、日平均胰岛素剂量、不良反应。结果 两组治疗后HbA1c、FPG、2 hPBG水平低于治疗前，且IDegAsp组低于IGlar组（P＜0.05）；IDegAsp组LAGE、PPGE小于IGlar组（P＜0.05）；IDegAsp组FINS高于IGlar组，HOMA-IR低于IGlar组（P＜0.05）；两组治疗后体重指数均大于治疗前，但IDegAsp组体重指数小于IGlar组，且日平均胰岛素剂量少于IGlar组（P＜0.05）；DegAsp组不良反应发生率低于IGlar组（P＜0.05）。结论 IDegAsp与IGlar对口服降糖药控制不佳T2DM患者均具有确切降糖作用，但IDegAsp的降糖效果更为显著，其用药剂量更少，可减少胰岛素治疗引起的血糖波动及体重变化，改善胰岛功能，降低低血糖等发生风险。
Abstract:
Objective To explore the clinical efficacy of insulin degludec/insulin aspart (IDegAsp) and insulin glargine (IGlar) in the treatment of type 2 diabetes mellitus with poor control of oral hypoglycemic drugs.Methods A total of 84 T2DM patients with poor control of oral hypoglycemic drugs admitted to Tianjin Wuqing District People’s Hospital from March 2020 to March 2022 were selected as the research objects. They were divided into IDegAsp group (42 patients) and IGlar group (42 patients) by random number table method. IDegAsp group was treated with insulin degludec/insulin aspart, and IGlar group was treated with insulin glargine. The blood glucose indexes [glycosylated hemoglobin (HbA1c), fasting blood glucose (FPG), 2 h postprandial blood glucose (2 hPBG)], blood glucose fluctuation [largest amplitude of glycemic excursion (LAGE), postprandial glucose fluctuation (PPGE)], islet function [fasting insulin (FINS), insulin resistance index HOMA-IR)], body mass index, daily average insulin dose and adverse reactions were compared between the two groups.Results After treatment, the levels of HbA1 c, FPG and 2 hPBG in the two groups were lower than those before treatment, and those in the IDegAsp group were lower than those in the IGlar group (P<0.05). LAGE and PPGE in IDegAsp group were lower than those in IGlar group (P<0.05). FINS in IDegAsp group was higher than that in IGlar group, and HOMA-IR was lower than that in IGlar group (P<0.05). The body mass index of the two groups after treatment was higher than that before treatment, but the body mass index of the IDegAsp group was lower than that of the IGlar group, and the daily average insulin dose was less than that of the IGlar group (P<0.05). The incidence of adverse reactions in the DegAsp group was lower than that in the IGlar group (P<0.05).Conclusion IDegAsp and IGlar have definite hypoglycemic effects on T2DM patients with poor control of oral hypoglycemic drugs, but the hypoglycemic effect of IDegAsp is more significant, and its dosage is less, which can reduce the blood glucose fluctuation and weight change caused by insulin treatment, improve islet function and reduce the risk of hypoglycemia.

参考文献/References:

[1]王艳妮,张逢,胡杰,等.门冬胰岛素30强化治疗2型糖尿病对血糖、血脂、胰岛β细胞功能的影响[J].西部医学,2018,30(8):1191-1194.[2]姚明言,张靖,王杰,等.利拉鲁肽联合德谷胰岛素对2型糖尿病患者血糖波动的影响[J].天津医药,2022,50(6):663-667.[3]Kalkman DN,Woudstra P,Heijer PD,et al.One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent[J].International Journal of Cardiology,2017,226(1):60-64.[4]卓璐,马雪菲,杨昌伟,等.德谷胰岛素和甘精胰岛素在中国北方1型糖尿病患者中血糖控制方面的差异性研究[J].实用药物与临床,2022,25(3):221-227.[5]母义明,郭立新,李玲,等.德谷胰岛素和甘精胰岛素在未经胰岛素治疗的2型糖尿病受试者中的疗效和安全性比较：一项国际多中心随机对照研究的中国亚组结果[J].中华内科杂志,2017,56(9):660-666.[6]Glastras SJ,Cohen N,Dover T,et al.The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes:An Empirical Perspective from Experience in Australia[J].Journal of Clinical Medicine,2020,9(4):1091-1107.[7]宋玉莲,薛冀苏,陈慧,等.德谷门冬双胰岛素治疗2型糖尿病的短期疗效观察[J].兰州大学学报(医学版),2022,48(2):37-41.[8]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398.[9]王昕,杨文英,马建华,等.2型糖尿病患者每日两次德谷门冬双胰岛素或双时相门冬胰岛素30治疗的糖化血红蛋白达标预测因子——德谷门冬双胰岛素中国Ⅲ期临床注册研究事后分析[J].中国糖尿病杂志,2021,29(10):742-748.[10]杨华,许学忠,祁平,等.甘精胰岛素注射液联合阿卡波糖片治疗继发性磺脲类药物失效的2型糖尿病的临床研究[J].中国临床药理学杂志,2017,33(3):219-221.[11]叶丛丛,姜辉,潘丽琴.甘精胰岛素联合口服降糖药治疗2型糖尿病的临床观察[J].北京医学,2018,40(2):115-117.[12]王曹锋,蔡文玮,陈谊,等.阿卡波糖控制不佳的老年2型糖尿病患者联合甘精胰岛素或中效胰岛素对血糖的影响[J].老年医学与保健,2017,23(2):105-108.[13]陆锦昆,潘琼华,潘海林,等.甘精胰岛素与门冬胰岛素30对2型糖尿病患者胰岛β细胞功能及血糖稳定性的影响[J].广西医科大学学报,2019,36(1):27-30.[14]Mccrimmon RJ,Sifri SA,Emral R,et al.Advancing therapy with iGlarLixi versus Premix 70/30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMixrandomised controlled trial[J].Diabetes Obesity and Metabolism,2021,23(6):1221-1231.[15]朱四民,徐毅,谢晔,等.德谷门冬双胰岛素注射液治疗2型糖尿病临床效果及安全性观察[J].解放军医药杂志,2022,34(5):61-63.[16]赵传志,陈凤玲.德谷胰岛素联合GLP-1 RAs对2型糖尿病患者Omentin-1、VaspinRBP4水平的影响[J].河北医药,2022,44(5):704-707.[17]罗琼,周黎,胡明.德谷门冬双胰岛素对比甘精胰岛素联合门冬胰岛素治疗基础胰岛素控制不佳的2型糖尿病患者的短期成本-效果分析[J].药物流行病学杂志,2022,31(7):481-485.[18]史雨清,杨昱,王苏,等.德谷门冬双胰岛素对比双相门冬胰岛素30治疗2型糖尿病疗效及安全性评价的荟萃分析[J].东南大学学报(医学版),2022,41(2):176-182.[19]朱大龙,赵维纲,匡洪宇,等.德谷门冬双胰岛素临床应用专家指导意见[J].中华糖尿病杂志,2021,13(7):695-701.[20]李婷,吕思清,王梦君,等.德谷胰岛素治疗老年2型糖尿病对空腹血糖、体质量指数和血糖波动的影响[J].检验医学与临床,2020,17(19):2891-2892.[21]王芳旭,张磊,陶立波.德谷门冬双胰岛素对比甘精胰岛素治疗口服降糖药控制不佳的中国2型糖尿病患者的成本-效果[J].中国药物经济学,2020,15(7):24-30.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(11):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(11):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(11):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(11):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(11):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
　LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(11):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
　DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(11):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(11):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
　LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(11):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
　BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Journal of Medical Information,2018,31(11):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]

更新日期/Last Update: 1900-01-01